Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Tae Won Mulsan Co., Ltd. is a multinational company engaged in the manufacturing and distribution of chemical products. As a key player in the chemical industry, the company's primary function is to supply essential materials that serve as integral components for various industrial applications, including pharmaceuticals, textiles, and agriculture. Tae Won Mulsan is known for its production of chemical intermediates, basic chemicals, and specialty chemicals. Its products are vital for the synthesis of more complex compounds and are essential in numerous manufacturing processes across diverse sectors. Tae Won Mulsan Co., Ltd. has a significant impact on the industries it serves, ensuring the supply of raw materials necessary for production chains worldwide. In the financial market, the company occupies a strategic position among chemical manufacturers, contributing to the dynamics and competitiveness of the sector by focusing on quality, innovation, and sustainability in its production processes. The company’s extensive product range and sizeable distribution network play a crucial role in maintaining its market significance and continuing influence within the global chemical industry landscape.
€2,600.00
€80.00 (-2.99%)
Live · 05:26 PM
The business is unprofitable at the operating level (-6.58% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 28.5%, still solid. Free cash flow declined 401% despite revenue growth, conversion is weakening.
Free cash flow declined 401% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -₩4.99B. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩15.90B
▲ +28.5% YoY
Net Income (TTM)
-₩3.05B
▼ -113.4% YoY
Op. Margin
-8.82%
▲ +1.1pp YoY
ROIC
-1.78%
▲ +0.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-₩37M
▼ -401.3% YoY
Op. Cash Flow (TTM)
₩2.45B
▼ -130.0% YoY
Net Debt
-₩35.50B
Net Cash Position
Cash & Equiv.
₩35.52B
3Y CAGR: +10.7%
Continue Research
Tae Won Mulsan Co. (001420.XKRX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Tae Won Mulsan Co. scores 27/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Tae Won Mulsan Co. scores 27 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -8.8% operating margin and a -1.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh 001420.XKRX's valuation and scores 27/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.